^
    Back
    Association details:
    Biomarker:HER-2 amplification
    Cancer:Salivary Gland Cancer
    Drug:Herceptin (trastuzumab) (HER2 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    Trastuzumab in Treating Patients With Metastatic or Recurrent Salivary Gland Cancer

    Excerpt:
    ...- Patients must have tumors that car HER-2 gene amplification as determined by (i) fluorescence in situ hybridization (FISH) or (ii) overexpression of HER-2 protein, 2+ to 3+ level assessed by immunohistochemistry...
    Trial ID:
    NCT00126607
    Evidence Level:
    Sensitive: C4 – Case Studies
    Source:
    Editage
    Title:

    Significant and durable clinical benefit from trastuzumab in 2 patients with HER2-amplified salivary gland cancer and a review of the literature

    Excerpt:
    We describe 1 patient with metastatic CEPA and 1 patient with metastatic recurrent salivary duct carcinoma whose tumors were evaluated by comprehensive genomic profiling. Testing identified human epidermal growth factor receptor 2 (HER2) amplification in both patients, and an additional activating HER2 mutation in the CEPA case....Both patients were treated with the HER2-targeting monoclonal antibody trastuzumab (herceptin) plus chemotherapy and experienced rapid responses.
    Secondary therapy:
    Chemotherapy
    DOI:
    https://doi.org/10.1002/hed.24634